Emerging and investigational targeted chemotherapy and immunotherapy agents for metastatic brain tumors / J. Tanner McMahon, Razan R. Faraj, David Cory Adamson
ABSTRACT Introduction Metastases to the central nervous system are the most common cause of malignant intracranial tumors in adults. Current standard of care includes surgery and radiation, but overall survival remains poor. A range of systemic therapies are emerging as promising treatment options for these patients. Areas covered This study reviews novel drug regimens that are under investigation in phase 1 and 2 clinical trials. To identify relevant therapies under clinical investigation, a search was performed on http://clinicaltrials.gov and Pubmed with the keywords brain metastasis, Phase I clinical trial, and Phase II clinical trial from 2016 to 2020. The authors detail the mechanisms of action of all trial agents, outline evidence for their utility, and summarize the current state of the field. Expert opinion Current advancements in the medical management of brain metastases can be categorized into targeted therapies, methods of overcoming treatment resistance, novel combinations of therapies, and modulation of the tumor microenvironment with a specific focus on immunotherapy. Each of these realms holds great promise for the field going forward. A more streamlined structure for enrollment into clinical trials will be a crucial step in accelerating progress in this area.
| Medienart: |
E-Artikel |
|---|
| Erscheinungsjahr: |
2020 |
|---|---|
| Erschienen: |
2020 |
| Enthalten in: |
Zur Gesamtaufnahme - volume:29 |
|---|---|
| Enthalten in: |
Expert opinion on investigational drugs - 29(2020), 12, Seite 1389-1406 |
| Sprache: |
Englisch |
|---|
| Beteiligte Personen: |
McMahon, J. Tanner [VerfasserIn] |
|---|
| Links: |
FID Access [lizenzpflichtig] |
|---|
| Themen: |
Brain metastasis |
|---|
| Umfang: |
1 Online-Ressource (18 p) |
|---|
| doi: |
10.1080/13543784.2020.1836154 |
|---|
| funding: |
|
|---|---|
| Förderinstitution / Projekttitel: |
|
| PPN (Katalog-ID): |
KFL011201444 |
|---|
| LEADER | 01000caa a22002652 4500 | ||
|---|---|---|---|
| 001 | KFL011201444 | ||
| 003 | DE-627 | ||
| 005 | 20230720210244.0 | ||
| 007 | cr uuu---uuuuu | ||
| 008 | 230714s2020 xx |||||o 00| ||eng c | ||
| 024 | 7 | |a 10.1080/13543784.2020.1836154 |2 doi | |
| 035 | |a (DE-627)KFL011201444 | ||
| 035 | |a (KFL)prod_LgpH_10.1080/13543784.2020.1836154 | ||
| 040 | |a DE-627 |b ger |c DE-627 |e rakwb | ||
| 041 | |a eng | ||
| 084 | |a PHARM |q DE-84 |2 fid | ||
| 100 | 1 | |a McMahon, J. Tanner |e verfasserin |4 aut | |
| 245 | 1 | 0 | |a Emerging and investigational targeted chemotherapy and immunotherapy agents for metastatic brain tumors |c J. Tanner McMahon, Razan R. Faraj, David Cory Adamson |
| 264 | 1 | |c 2020 | |
| 300 | |a 1 Online-Ressource (18 p) | ||
| 336 | |a Text |b txt |2 rdacontent | ||
| 337 | |a Computermedien |b c |2 rdamedia | ||
| 338 | |a Online-Ressource |b cr |2 rdacarrier | ||
| 520 | |a ABSTRACT Introduction Metastases to the central nervous system are the most common cause of malignant intracranial tumors in adults. Current standard of care includes surgery and radiation, but overall survival remains poor. A range of systemic therapies are emerging as promising treatment options for these patients. Areas covered This study reviews novel drug regimens that are under investigation in phase 1 and 2 clinical trials. To identify relevant therapies under clinical investigation, a search was performed on http://clinicaltrials.gov and Pubmed with the keywords brain metastasis, Phase I clinical trial, and Phase II clinical trial from 2016 to 2020. The authors detail the mechanisms of action of all trial agents, outline evidence for their utility, and summarize the current state of the field. Expert opinion Current advancements in the medical management of brain metastases can be categorized into targeted therapies, methods of overcoming treatment resistance, novel combinations of therapies, and modulation of the tumor microenvironment with a specific focus on immunotherapy. Each of these realms holds great promise for the field going forward. A more streamlined structure for enrollment into clinical trials will be a crucial step in accelerating progress in this area | ||
| 653 | |a Brain metastasis | ||
| 653 | |a lung cancer | ||
| 653 | |a melanoma | ||
| 653 | |a breast cancer | ||
| 653 | |a renal cell carcinoma | ||
| 653 | |a clinical trials | ||
| 653 | |a immunotherapy | ||
| 653 | |a tyrosine kinase inhibitors | ||
| 653 | |a small molecule inhibitors | ||
| 653 | |a early phase trial | ||
| 700 | 1 | |a Faraj, Razan R. |e verfasserin |4 aut | |
| 700 | 1 | |a Adamson, David Cory |e verfasserin |4 aut | |
| 773 | 0 | 8 | |i Enthalten in |t Expert opinion on investigational drugs |d Abingdon, Oxon : Routledge, Taylor & Francis, 1994 |g 29(2020), 12, Seite 1389-1406 |h Online-Ressource |w (DE-627)KFL000006041 |w (DE-600)2030114-5 |w (DE-576)302969314 |x 1744-7658 |7 nnns |
| 773 | 1 | 8 | |g volume:29 |g year:2020 |g number:12 |g pages:1389-1406 |
| 856 | 4 | 0 | |u http://pharmazie.proxy.fid-lizenzen.de/fid/tandf-ejournals-pharmazie/doi.org/10.1080/13543784.2020.1836154 |m X:KFL |x Resolving-System |y FID Access |z lizenzpflichtig |
| 912 | |a ZDB-1-TFE | ||
| 912 | |a GBV_KFL | ||
| 912 | |a FID-PHARM | ||
| 935 | |i IMPORT_0628_prod_LgpH_02 | ||
| 951 | |a AR | ||
| 952 | |d 29 |j 2020 |e 12 |h 1389-1406 | ||